Appetite suppressants and valvular heart disease - A systematic review

BMC Clinical Pharmacology

Volumn 2, Issue , 2002, Pages

  Loke, Yoon K ^a   Derry, Sheena ^a   Pritchard Copley, Angharad ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; DEXFENFLURAMINE; FENFLURAMINE; PHENTERMINE;

AORTA VALVE REGURGITATION; CLINICAL STUDY; CLINICAL TRIAL; CONFIDENCE INTERVAL; DISEASE COURSE; DISEASE SEVERITY; DRUG EXPOSURE; ECHOCARDIOGRAPHY; EVIDENCE BASED MEDICINE; HUMAN; MITRAL VALVE REGURGITATION; OBESITY; OUTCOMES RESEARCH; RANDOMIZATION; REVIEW; RISK ASSESSMENT; VALVULAR HEART DISEASE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS;

APPETITE DEPRESSANTS; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; DEXFENFLURAMINE; FENFLURAMINE; HEART VALVE DISEASES; HUMANS; PHENTERMINE;

EID: 0003376125     PISSN: 14726904     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-2-6     Document Type: Review

References (28)

1. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV: Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997, 337:581-588
2. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep 1997, 46:1061-1066
3. Schiller NB: Fen/phen and valvular heart disease: if it sounds too bad to be true, perhaps it isn't. J Am Coll Cardiol 1999, 34:1159-1162
4. Burger AJ, Charlamb MJ, Singh S, Notarianni M, Blackburn GL, Sherman HB: Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs. Int J Cardiol 2001, 79:159-165
5. Fisher EA, Ruden R: Pulmonary artery pressures and valvular lesions in patients taking diet suppressants. Cardiovasc Rev Rep 1998, 19:13-16
6. Kancherla MK, Salti HI, Mulderink TA, Parker M, Bonow RO, Mehlman DJ: Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluraminephentermine combination or to dexfenfluramine. Am J Cardiol 1999, 84:1335-1338
7. Lepor NE, Gross SB, Daley WL, Samuels BA, Rizzo MJ, Luko SP, Hickey A, Buchbinder NA, Naqvi TZ: Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease. Am J Cardiol 2000, 86:107-110
8. Teramae CY, Connolly HM, Grogan M, Miller FA Jr: Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience. Mayo Clin Proc 2000, 75:456-461
9. Wadden TA, Berkowitz RI, Silvestry F, Vogt RA, St John Sutton MG, Stunkard AJ, Foster GD, Aber JL: The fen-phen finale: a study of weight loss and valvular heart disease. Obes Res 1998, 6:278-284
10. Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL: Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000, 283:1703-1709
11. Hensrud DD, Connolly HM, Grogan M, Miller FA, Bailey KR, Jensen MD: Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. Mayo Clin Proc 1999, 74:1191-1197
12. Jollis JG, Landolfo CK, Kisslo J, Constantine GD, Davis KD, Ryan T: Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation 2000, 101:2071-2077
13. Khan MA, Herzog CA, St. Peter JV, Hartley GG, Madlon-Kay R, Dick CD, Asinger RW, Vessey JT: The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998, 339:713-718
14. Shively BK, Roldan CA, Gill EA, Najarian T, Loar SB: Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation 1999, 100:2161-2167
15. Wee CC, Phillips RS, Aurigemma G, Erban S, Kriegel G, Riley M, Douglas PS: Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication. Ann Intern Med 1998, 129:870-874
16. Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT: An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. N Engl J Med 1998, 339:725-732
17. Weissman NJ: Appetite suppressant valvulopathy: a review of current data. Cardiovasc Rev Rep 1999, 20:146-155
18. Weissman NJ, Panza JA, Tighe JF, Gwynne JT: Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001, 134:267-273
19. Mast ST, Jollis JG, Ryan T, Anstrom KJ, Crary JL: The progression of fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Intern Med 2001, 134:261-266
20. Moore RA, Gavaghan D, Tramer MR, Collins SL, McQuay HJ: Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998, 78:209-216
21. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP: Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998, 352:609-613
22. Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R: The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology 1994, 44:16-20
23. Arnaiz JA, Carné X, Riba N, Codina C, Ribas J, Trilla A: The use of evidence in pharmacovigilance: case reports as the reference source for drug withdrawals. Eur J Clin Pharmacol 2001, 57:89-91
24. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE: A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998, 339:719-724
25. Jick H: Heart valve disorders and appetite-suppressant drugs. JAMA 2000, 283:1738-1740
26. Fishman AP: Aminorex to fen/phen: an epidemic foretold. Circulation 1999, 99:156-161
27. British Broadcasting Corporation News: Slimming pill doctor struck off. [http://news.bbc.co.uk/hi/english/uk/wales/newsid_1634000/ 1634208.stm]18 June 2002
28. Metcalfe K, Corns C, Fahie-Wilson M, Mackenzie P: Chinese medicines for slimming still cause health problems. BMJ 2002, 324:679